On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating. FDA settled on targeting JN.1 — the variant responsible for most Covid cases of early this year. A vaccine targeting JN. 1 should offer broader protection against its offshoots KP.2, KP.3 and others that may pop ...

Shares of the biotechnology company have appreciated by 28.73% over the course of the past month, outperforming the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.46 per share and revenue of $4.05 billion. These totals would mark changes of +39.5% and -40.83%, respectively, from last year. Our research reveals that these estimate alterations are directly linked with the stock price perform ...

Moderna, Inc. (MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic. The regulatory filing is based on guidance from the FDA last week, whereby the regulatory body advised eminent vaccine manufacturers like Moderna, Novavax (NVAX) and Pfizer (PFE) to update their respective COVID-19 vaccines to a monovalent (single strain) JN.1 compositio ...

Moderna has announced promising data on a combination COVID-flu vaccine. This trial tested the combination vaccine in two groups of roughly 4,000 adults, one aged 65 and older and other between 50 and 64 years, and used blood tests to assess the strength of immune response generated by two different vaccines for the viruses administered at the same time. Moderna has not published data from the trial or opened it up to external scrutiny but said it plans to present data at an upcoming medical conference and ...

The biotech company is the first to release positive phase three data on a Covid and flu combination shot, giving it a potential lead over rival vaccine makers Pfizer and Novavax. Bancel added that combination shots could reduce the burden of respiratory viruses on pharmacists and the broader U.S. health-care system, which has been grappling with a labor shortage that has many workers stretched thin. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's current ...

This messenger-RNA pioneer should be able to keep its rebound going. Some investors might view Moderna (MRNA -2.38%) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year. The real story for Moderna is much better than that steep sales decline reflects. Here's why the biotech stock is a no-brainer buy right now. At an inflection point It's no exaggeration to say that Moderna ...

NEW YORK, June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Moderna and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 31, 2024, Moderna iss ...

UCG/Universal Images Group via Getty Images Invest with Trefis Market Beating Portfolios Trefis Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi ... [+] Images/GHI/UCG/Universal Images Group via Getty Images) Even if we look at a slightly longer term, MRNA stock has seen strong gains of 50% from levels of $105 in early January 2021 to around $155 now, vs. an increase of about 40% for the S&P 500 over this roughly threeyear period. However, the increase in MRNA stock has b ...

Jamey Mock Jamey Mock Jamey Mock Jamey Mock Jamey Mock Jamey Mock Jamey Mock Jamey Mock Jamey Mock Michael Yee Jamey Mock And then open the cap. Michael Yee Correct. Jamey Mock When we tried to do it. Kudos to these who do all this because they got to do it 10 times a day. And my point is, there is multiple steps. Now that said, when we looked at it, GSK and Pfizer have sort of gotten it down to sort of like four steps. And like one of them, I think Pfizer is nine steps, but then they turn nine steps into f ...

Moderna, Inc. (NASDAQ:MRNA) Jefferies 2024 Global Healthcare Conference June 6, 2024 10:00 AM ET Company Participants Jamey Mock - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee [Starts Abruptly] of Moderna, Jamey Mock, up here with us. Jamey, it's great to be here. Last I checked, you have a second product that is going to be generating revenue. So, that's very exciting. We'll talk about that, in RSV. You just got back from ASCO, a long week at ASCO talking about the pipeline and with ...